Cullinan Competitors
| CGEM Stock | USD 12.23 0.38 3.21% |
Cullinan Oncology vs Bicycle Therapeutics Correlation
Average diversification
The correlation between Cullinan Oncology LLC and BCYC is 0.15 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Cullinan Oncology LLC and BCYC in the same portfolio, assuming nothing else is changed.
Moving together with Cullinan Stock
Moving against Cullinan Stock
| 0.67 | GNLX | Genelux Common | PairCorr |
| 0.61 | LYRA | Lyra Therapeutics | PairCorr |
| 0.6 | QSI | QuantumSi | PairCorr |
| 0.59 | EDIT | Editas Medicine | PairCorr |
| 0.57 | EVGN | Evogene | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cullinan Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cullinan Oncology Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Cullinan Oncology and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Cullinan and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Cullinan Oncology LLC does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Cullinan Stock performing well and Cullinan Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cullinan Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| LAB | 3.06 | 0.06 | 0.00 | 0.19 | 3.36 | 7.81 | 25.50 | |||
| SY | 3.63 | (0.09) | 0.00 | 0.04 | 5.33 | 7.04 | 31.96 | |||
| ADCT | 3.29 | 0.02 | (0.01) | 0.28 | 4.37 | 8.49 | 22.84 | |||
| RAPT | 3.89 | 1.16 | 0.31 | 0.76 | 2.95 | 7.87 | 64.19 | |||
| CBLL | 2.59 | 0.92 | 0.38 | 0.82 | 1.87 | 6.82 | 18.00 | |||
| EHAB | 1.65 | 0.45 | 0.21 | 1.31 | 1.50 | 4.81 | 11.79 | |||
| VREX | 1.58 | 0.18 | 0.06 | 0.23 | 2.97 | 3.76 | 17.42 | |||
| NMRA | 3.83 | (0.21) | 0.00 | (0.08) | 0.00 | 9.77 | 33.25 | |||
| OMER | 5.57 | 1.21 | 0.21 | 3.76 | 4.39 | 12.62 | 87.69 | |||
| BCYC | 2.89 | (0.35) | 0.00 | (0.94) | 0.00 | 6.06 | 14.20 |
Cross Equities Net Income Analysis
Compare Cullinan Oncology LLC and related stocks such as Standard Biotools, So Young International, and ADC Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LAB | (23.6 M) | (22.5 M) | (19 M) | (15.8 M) | (52.8 M) | (53.3 M) | (76 M) | (60.5 M) | (59 M) | (64.8 M) | (53 M) | (59.2 M) | (190.1 M) | (74.7 M) | (138.9 M) | (125 M) | (118.7 M) |
| SY | (81 M) | (81 M) | (81 M) | (81 M) | (81 M) | (81 M) | (81 M) | 17.2 M | 55.1 M | 176.7 M | 5.8 M | (8.4 M) | (65.6 M) | 21.3 M | (589.5 M) | (530.6 M) | (504 M) |
| ADCT | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (123.1 M) | (116.5 M) | (246.3 M) | (230 M) | (157.1 M) | (240.1 M) | (157.8 M) | (142.1 M) | (149.2 M) |
| RAPT | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (36.1 M) | (43 M) | (52.9 M) | (68.2 M) | (81.9 M) | (116.8 M) | (129.9 M) | (116.9 M) | (111 M) |
| CBLL | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (29.5 M) | (40.5 M) | (36.4 M) | (38.2 M) |
| EHAB | 24 M | 24 M | 24 M | 24 M | 24 M | 24 M | 24 M | 24 M | 24 M | 24 M | 75 M | 111.1 M | (40.4 M) | (80.5 M) | (156.2 M) | (140.6 M) | (133.6 M) |
| VREX | 109.6 M | 109.6 M | 109.6 M | 110.1 M | 80 M | 68.5 M | 51.6 M | 27.5 M | 15.5 M | (57.9 M) | 17.4 M | 30.3 M | 48.2 M | (47.7 M) | (69.9 M) | (62.9 M) | (59.8 M) |
| NMRA | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (237.3 M) | (130.9 M) | (235.9 M) | (243.8 M) | (219.4 M) | (230.4 M) |
| OMER | (7.4 M) | (28.5 M) | (38.4 M) | (39.8 M) | (73.7 M) | (75.1 M) | (66.7 M) | (53.5 M) | (126.8 M) | (84.5 M) | (138.1 M) | (111.4 M) | 47.4 M | (117.8 M) | (156.8 M) | (141.1 M) | (134.1 M) |
| BCYC | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (16.3 M) | (21.8 M) | (30.6 M) | (51 M) | (66.8 M) | (112.7 M) | (180.7 M) | (169 M) | (152.1 M) | (144.5 M) |
Cullinan Oncology LLC and related stocks such as Standard Biotools, So Young International, and ADC Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Cullinan Oncology LLC financial statement analysis. It represents the amount of money remaining after all of Cullinan Oncology LLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Cullinan Oncology Competitive Analysis
The better you understand Cullinan Oncology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Cullinan Oncology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Cullinan Oncology's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Cullinan Oncology Competition Performance Charts
Five steps to successful analysis of Cullinan Oncology Competition
Cullinan Oncology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Cullinan Oncology LLC in relation to its competition. Cullinan Oncology's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Cullinan Oncology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Cullinan Oncology's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Cullinan Oncology LLC, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Cullinan Oncology position
In addition to having Cullinan Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Climate Change Thematic Idea Now
Climate Change
Large and medium sized entities that are committing to fully or partially replace some traditional services or products with renewables sources of energy in order to combat global climate change. The Climate Change theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Climate Change Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Cullinan Oncology Correlation with its peers. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Will Biotechnology sector continue expanding? Could Cullinan diversify its offerings? Factors like these will boost the valuation of Cullinan Oncology. Projected growth potential of Cullinan fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cullinan Oncology data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Cullinan Oncology LLC using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cullinan Oncology's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Cullinan Oncology's market price to deviate significantly from intrinsic value.
It's important to distinguish between Cullinan Oncology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cullinan Oncology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cullinan Oncology's market price signifies the transaction level at which participants voluntarily complete trades.